Document is current
Any future updates will be listed below
-
Authors
Herrle, Niklas
Malacarne, Pedro F https://orcid.org/0000-0002-9561-5985
Warwick, Timothy https://orcid.org/0000-0002-6804-2931
Cabrera-Orefice, Alfredo
Chen, Yiheng
Gheisari, Maedeh
Chatterjee, Souradeep https://orcid.org/0000-0002-5668-040X
Leisegang, Matthias S https://orcid.org/0000-0002-6084-6484
Sarakpi, Tamim
Wionski, Sarah
Lopez, Melina https://orcid.org/0000-0001-7107-3109
Kader, Carine https://orcid.org/0009-0007-7566-1136
Teichmann, Tom
Drekolia, Maria-Kyriaki
Koch, Ina https://orcid.org/0000-0002-3621-003X
Keßler, Marcus https://orcid.org/0000-0002-5652-8424
Klein, Sabine
Erhard Uschner, Frank
Trebicka, Jonel
Brunst, Steffen
Proschak, Ewgenij
Günther, Stefan https://orcid.org/0000-0002-5594-4549
Rosas-Lemus, Mónica
Baumgarten, Nina https://orcid.org/0000-0002-5423-8634
Klatt, Stephan https://orcid.org/0000-0003-0064-3367
Speer, Thimoteus
Bibli, Sofia-Iris
Segarra, Marta https://orcid.org/0000-0002-0956-8490
Acker-Palmer, Amparo https://orcid.org/0000-0002-8107-927X
Wagner, Julian U G
Wittig, Ilka
Dimmeler, Stefanie
Schulz, Marcel H https://orcid.org/0000-0002-1252-3656
Richards, J B
Gilsbach, Ralf
T Denton, Travis
Fleming, Ingrid https://orcid.org/0000-0003-1881-3635
Hannibal, Luciana
Brandes, Ralf P https://orcid.org/0000-0002-8035-0048
Rezende, Flávia https://orcid.org/0000-0001-7864-9131
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (456687919)
CIBSS-EXC2189 (390939984)
ECCPS (390649896)
Deutsches Zentrum für Herz-Kreislaufforschung
Medicine Faculty Goethe University
- License Information
-
More Information
Article History
Received: 11 February 2025
Revised: 26 September 2025
Accepted: 15 October 2025
First Online: 17 December 2025
Disclosure and competing interests statement
: The authors declare no conflict of interest that could potentially influence or bias the work. TD co-owns LiT Biosciences. The company did not contribute funding to the current manuscript or to any work previously carried out by the authors. JBR is the CEO of 5 Prime Sciences ( ), which provides research services for biotech, pharma, and venture capital companies for projects unrelated to this research. He has served as an advisor to GlaxoSmithKline and Deerfield Capital. JBR’s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline, and Biogen for projects unrelated to this research. YC is an employee of 5 Prime Sciences. JT has received speaking and/or consulting fees from Astra-Zeneca, Gore, Boehringer-Ingelheim, Falk, Grifols, Genfit, and CSL Behring.
